There is some evidence that the pro-cancerous effects of TGF-β in the tumor cells occur at later stages of HCC, making TGF-β inhibitors attractive therapeutic options in advanced HCC [34,40]. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.